PT  - JOURNAL ARTICLE
AU  - Kockelmann, Fabian
AU  - Göhler, Daniel
AU  - Barbey, Sarah
AU  - Gena, Amayu Wakoya
AU  - Alsaad, Hayder
AU  - Voelker, Conrad
AU  - Zieren, Jürgen
AU  - Ouaissi, Mehdi
AU  - Giger-Pabst, Urs
TI  - Chemical/technical risk analysis of a new multi-directional nebulizer (MDN) and its clinical implementation for the safe administration of Pressurized Intraperitoneal Aerosol Chemotherapy (MDN-PIPAC)
AID  - 10.1101/2023.12.01.23297348
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.01.23297348
4099  - http://medrxiv.org/content/early/2023/12/15/2023.12.01.23297348.short
4100  - http://medrxiv.org/content/early/2023/12/15/2023.12.01.23297348.full
AB  - Background/Aim To test the chemoresistance of a multi-directional nebulizer (MDN) and to establish and implement a perioperative clinical safety concept for its clinical use to deliver pressurised intraperitoneal aerosol chemotherapy (MDN-PIPAC).Study design Ex-vivo nebulization of cytostatic drugs with the MDN device to assess chemoresistance/toxicological risks. Establishment of a perioperative safety concept for the clinical administration of MDN-PIPAC by ex- and in-vivo porcine simulation studies. Unicentric case series of 30 MDN-PIPACs in 21 patients with peritoneal surface malignancies (PSM). Endpoints were intraoperative adverse events and perioperative complications (Clavien-Dindo).Results Toxicological studies/risk assessment confirm the safety of administering PIPAC with the MDN. The horizontal nozzles must protrude at least 7 mm beyond the most distal end of the trocar tip and lateral tilting should be prevented by fixation of the device in a single-arm holder. A total of 21 patients (male/female ratio: 2:1) with a mean age of 62 (range: 38-86) years underwent 30 consecutive MDN-PIPACs for peritoneal surface malignancies of different origin. ECOG 0 and 1 were seen in five and 16 patients, respectively. Thirteen, seven, and one patient underwent one, two, and three MDN-PIPACs, respectively. Two patients received only one cycle of MDN-PIPAC because they were considered candidates for cytoreductive surgery and heated intraperitoneal chemotherapy. There were no intraoperative technical/medical problems observed. Four patients suffered from postoperative grade I complications.Conclusions Compounds leached during chemotherapy nebulization with the MDN are toxicologically safe. MDN-PIPAC administrations are safe and the postoperative course is comparable to that of the conventional PIPAC nebulizer.MINI ABSTRACT Toxicological analyses confirm that doxorubicin, cisplatin, and oxaliplatin nebulized with the MDN do not release leachables that pose a toxicological risk to patients. Through technical risk analysis and PIPAC simulations, a safety concept for the administration of MDN-PIPAC was established. No technical/medical intraoperative adverse events were observed. The perioperative course was comparable to that of the conventional axial single-direction nebulizer (SDN) PIPAC.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialDRKS00033077Funding StatementThe animal experiments, were funded by the Association Tourangelle de recherche en oncologie du val de Loire (AT-ROVL)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The approval of the Ethics Committee of the Medical Faculty of the University of Muenster and the Medical Association Westphalia-Lippe in Germany (file # 2021-360-f-s) was obtained. The study (file # 40583) was approved by the French Ministry of Higher Education and Research.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAETAnalytical Evaluation Threshold (ISO 10993-18 (2020)BSABody Surface Area calculated according to DuBoisCEConformité EuropéenneDGAVDeutsche Gesellschaft für Allgemein- und ViszeralchirurgieECOGEastern Cooperative Oncology GroupFDAU.S. Food and Drug AdministrationGC-MSGas Chromatography coupled with Mass SpectrometryHSGC-MSHead-space Gas Chromatography coupled with Mass SpectrometryICIon ChromatographyICP-OESInductively Coupled Plasma Atomic Emission SpectrometryLC-MSLiquid phase chromatography□coupled to a Mass SpectrometerMDNMulti-Directional Nebulizer (QuattroJet™, REGER Medizintechnik GmbH, Villigendorf, Germany)PCIPeritoneal Carcinomatosis Index according to SugarbakerPIPACPressurized IntraPeritoneal Aerosol ChemotherapyPSMPeritoneal Surface MalignanciesRIPACRotational intraperitoneal aerosol chemotherapySDNSingle-direction nebulizer